Clinical Trial Update: Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on camrelizumab combined with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma spanning Phase 1 and P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Esophageal Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN